- Home
- PC vs ATHE Comparison
PC vs ATHE Comparison
Compare PC & ATHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PC
- ATHE
- Stock Information
- Founded
- PC 2012
- ATHE 1997
- Country
- PC Singapore
- ATHE Australia
- Employees
- PC N/A
- ATHE N/A
- Industry
- PC Restaurants
- ATHE Biotechnology: Pharmaceutical Preparations
- Sector
- PC Consumer Discretionary
- ATHE Health Care
- Exchange
- PC Nasdaq
- ATHE Nasdaq
- Market Cap
- PC 11.1M
- ATHE 10.1M
- IPO Year
- PC 2024
- ATHE N/A
- Fundamental
- Price
- PC $0.73
- ATHE $1.11
- Analyst Decision
- PC
- ATHE Buy
- Analyst Count
- PC 0
- ATHE 1
- Target Price
- PC N/A
- ATHE $4.00
- AVG Volume (30 Days)
- PC 846.1K
- ATHE 12.9K
- Earning Date
- PC 11-26-2024
- ATHE 11-26-2024
- Dividend Yield
- PC N/A
- ATHE N/A
- EPS Growth
- PC N/A
- ATHE N/A
- EPS
- PC N/A
- ATHE N/A
- Revenue
- PC $3,809,288.00
- ATHE $2,681,669.00
- Revenue This Year
- PC N/A
- ATHE N/A
- Revenue Next Year
- PC N/A
- ATHE N/A
- P/E Ratio
- PC N/A
- ATHE N/A
- Revenue Growth
- PC N/A
- ATHE 2.63
- 52 Week Low
- PC $0.60
- ATHE $1.01
- 52 Week High
- PC $5.73
- ATHE $5.41
- Technical
- Relative Strength Index (RSI)
- PC N/A
- ATHE 38.28
- Support Level
- PC N/A
- ATHE $1.10
- Resistance Level
- PC N/A
- ATHE $1.29
- Average True Range (ATR)
- PC 0.00
- ATHE 0.07
- MACD
- PC 0.00
- ATHE 0.00
- Stochastic Oscillator
- PC 0.00
- ATHE 2.63
About PC Premium Catering (Holdings) Limited Ordinary Shares
Premium Catering (Holdings) Ltd is a company that conducts its operations through its subsidiary is mainly engaged in food catering for functions, events, and workers in Singapore. They specialize in Indian, Bangladesh, and Chinese cuisine and all its food products are Halal food which is permissible for consumption by Muslims to consume.
About ATHE Alterity Therapeutics Limited
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.